Karuna Therapeutics Entered into an Exclusive License Agreement with Goldfinch Bio for TRPC4/5 Product Candidates
Shots:
- Goldfinch Bio will receive $15M up front & is eligible to receive ~$520M in milestones for each licensed TRPC4/5 candidate from which $410M for regulatory approval & commercial sales milestones along with royalty on net sales of each licensed product
- Karuna to get the global development, manufacturing & commercialization rights to Goldfinch Bio’s transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, incl. GFB-887 for various psychiatric & neurological conditions. The development details of GFB-887 are expected in H2’23
- In preclinical models of mood & anxiety disorders, GFB-887 showed compelling benefits. Karuna will use its expertise in developing therapies for psychiatric disorders to advance TRPC4/5 candidate
Ref: Globe Newswire | Image: Karuna Therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
